About the Authors
- Yejun Wang
-
Contributed equally to this work with: Yejun Wang, Anneke van der Walt
Affiliation The Centre for Neuroscience Research, University of Melbourne, Parkville, Victoria, Australia
- Anneke van der Walt
-
Contributed equally to this work with: Yejun Wang, Anneke van der Walt
Affiliations The Centre for Neuroscience Research, University of Melbourne, Parkville, Victoria, Australia, The Department of Neurology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
- Mark Paine
-
Affiliation The Royal Victoria Eye and Ear Hospital, East Melbourne, Victoria, Australia
- Alexander Klistorner
-
Affiliation The Sydney Eye Hospital, Sydney, New South Wales, Australia
- Helmut Butzkueven
-
Affiliations Department of Medicine, University of Melbourne, Parkville, Victoria, Australia, The Department of Neurology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
- Gary F. Egan
-
Affiliation Monash Biomedical Imaging, Monash University, Clayton, Victoria, Australia
- Trevor J. Kilpatrick
-
Affiliations The Centre for Neuroscience Research, University of Melbourne, Parkville, Victoria, Australia, The Department of Neurology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
- Scott C. Kolbe
-
* E-mail: kolbes@unimelb.edu.au
Affiliation The Centre for Neuroscience Research, University of Melbourne, Parkville, Victoria, Australia
Competing Interests
Dr. van der Walt has received travel support from Bayer Australia and Sanofi Aventis. She has received unrestricted grants from Bayer Asutralia and Biogen Idec. Dr. Klistorner is supported by an unrestricted grant from Biogen Idec. Dr. Butzkueven has served on scientific advisory boards for Biogen Idec, Novartis and Sanofi-Aventis and has received conference travel support from Novartis, Biogen Idec andSanofi Aventis. He serves on steering committees for trials conducted by Merck Serono, Biogen Idec and Novartis. Dr. Butzkueven has received research support from Merck Serono, Novartis and Biogen Idec in his capacity as honorary chair of the MSBase Foundation. Dr. Kilpatrick has served on scientific advisory boards for GlaxoSmithKline, Neurosciences Victoria and the Victorian Neurotrauma Initiative; has received funding for travel from Bayer Schering pharma, Sanofi Aventis and Merck Serono; served on the editorial board of Therapeutic Advances in Neurological Disorders; is listed as an inventor on patents re: HIV test kit method for detecting anti-HIV-1 antibodies in saliva; A method of modulating cell survival and reagents useful for the same; Methods for the treatment and prophylaxis of demyelinating disease; and Method of treatment in the field of inflammatory neurodegeneration; and receives research support from Bayer Schering Pharma, Biogen IDEC. Dr. Egan serves on an ARC college of experts panel for which he receives personal compensation, he is a member of the Neurosciences Victoria scientific advisory board; he has received travel expenses and/or honoraria for lectures or educational activities not funded by industry; he is an associate editor of Human Brain Mapping, he serves on the editorial boards of Neuroimage and the Journal of Imaging Technology.
Author Contributions
Conceived and designed the experiments: AK MP SK TK AvdW HB GE. Performed the experiments: AK YW AvdW SK. Analyzed the data: AK SK YW AvdW. Contributed reagents/materials/analysis tools: SK YW. Wrote the paper: YW AvdW SK.